Many patients benefit from such treatments, exhibiting not only a higher objective response rate, but also durable remission for many years.1, 2, 3, 4, 5, 6 While treatment with PD‐1/PD‐L1 blockade can be highly effective, not every patient or cancer type responds to these inhibitors, and some patients experience hyperprogression after immunotherapy.7 Identifying which patients may benefit from these inhibitors is one of the most significant current challenges. Here, CD274 is linked to cancer.